Milan, Italy

Ezio Panto

This inventor holds 1 USPTO granted patent. Top assignee: Pierrel Spa. Active years: 1988.


% Patents Active = 100.0

Average Co-Inventor Count = 4.0

ph-index = 1

Forward Citations = 15(Granted Patents)


Company Filing History:


Years Active: 1988

Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovations of Ezio Panto

Introduction

Ezio Panto is a notable inventor based in Milan, Italy. He has made significant contributions to the field of chemistry, particularly in the development of new compounds with potential health benefits. His work focuses on creating innovative solutions that address various medical challenges.

Latest Patents

Ezio Panto holds a patent for "New 8-substituted nucleoside and purine derivatives." This patent describes a process for synthesizing these new compounds, which are characterized by a general formula that includes various substituents. The compounds exhibit antihyperlipaemic activity, indicating their potential use in managing lipid levels in the body. He has 1 patent to his name, showcasing his innovative approach to chemical research.

Career Highlights

Panto's career is marked by his dedication to advancing scientific knowledge and developing practical applications for his discoveries. He works at Pierrel Spa, a company known for its focus on pharmaceutical innovations. His role at the company allows him to collaborate with other experts in the field and contribute to groundbreaking research.

Collaborations

Throughout his career, Ezio Panto has collaborated with esteemed colleagues such as Silvano Casadio and Duccio Favara. These partnerships have enabled him to enhance his research and expand the impact of his inventions.

Conclusion

Ezio Panto's contributions to the field of chemistry and his innovative patents highlight his commitment to improving health outcomes through scientific research. His work continues to inspire future advancements in the industry.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…